Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany.
Feuerlein Center on Translational Addiction Medicine (FCTS), University of Heidelberg, Heidelberg, Germany.
Addict Biol. 2020 Jan;25(1):e12717. doi: 10.1111/adb.12717. Epub 2019 Feb 12.
During the first weeks of abstinence, alcohol craving in patients may increase or "incubate." We hypothesize that Naltrexone (NTX) blocks this incubation effect. Here, we compared NTX effects on neural alcohol cue reactivity (CR) over the first weeks of abstinence and on long-term clinical outcomes to standard treatment. Male alcohol-dependent patients (n = 55) and healthy controls (n = 35) were enrolled. Participants underwent baseline psychometric testing and functional magnetic resonance imaging (fMRI) assessment of mesolimbic alcohol CR. Patients participated in a standard treatment program with the option of adjuvant NTX. They received another scan after 2 weeks of treatment. We found higher CR in several brain regions in patients versus healthy controls. CR significantly increased over 2 weeks in the standard treatment group (n = 13) but not in the NTX group (n = 22). NTX significantly attenuated CR in the left putamen and reduced relapse risk to heavy drinking within 3 months of treatment. Additionally, increased CR in the left putamen and its course over time predicted both NTX response and relapse risk. Carrier status for the functional OPRM1 variant rs1799971:A > G was considered but had no effect on NTX efficacy. In conclusion, NTX was most effective in patients with high CR in the left putamen. While the results from our naturalistic study await further confirmation from prospective randomized trials, they support a potential role of neural CR as a biomarker in the development of precision medicine approaches with NTX.
在戒断的最初几周,患者的酒精渴求可能会增加或“酝酿”。我们假设纳曲酮(NTX)可以阻断这种潜伏期效应。在这里,我们比较了 NTX 对戒断最初几周内神经酒精线索反应性(CR)的影响及其与标准治疗的长期临床结局。纳入了 55 名男性酒精依赖患者和 35 名健康对照者。参与者接受了基线心理测试和中脑边缘系统酒精 CR 的功能磁共振成像(fMRI)评估。患者参加了标准治疗计划,并可选择辅助使用 NTX。治疗 2 周后,他们接受了另一次扫描。与健康对照组相比,我们发现患者的几个大脑区域的 CR 更高。在标准治疗组(n=13)中,CR 在 2 周内显著增加,但在 NTX 组(n=22)中没有增加。NTX 可显著减轻左壳核的 CR,并降低治疗后 3 个月内重度饮酒的复发风险。此外,左壳核的 CR 增加及其随时间的变化,既预测了 NTX 的反应,也预测了复发风险。虽然考虑了功能性 OPRM1 变体 rs1799971:A>G 的携带状态,但它对 NTX 的疗效没有影响。总之,NTX 在左壳核 CR 较高的患者中最有效。虽然我们的自然主义研究结果有待前瞻性随机试验进一步证实,但它们支持将神经 CR 作为 NTX 开发精准医学方法的生物标志物的潜在作用。